Enhancing RNA Drug Delivery for Genetic Treatments

A recent study conducted by researchers at the University of Basel highlights how manipulating the transport of RNA-based drugs within cells can enhance their effectiveness in treating genetic diseases. This innovative approach focuses on improving the action of antisense oligonucleotides (ASOs), which have shown potential in addressing previously untreatable genetic disorders such as Amyotrophic Lateral Sclerosis (ALS) and Duchenne muscular dystrophy.

The Challenge of RNA Therapy

Although ASOs are promising therapeutics, their efficacy is often hindered by an inability to reach their intended intracellular targets. Once delivered into cells, ASOs enter sorting organelles known as endosomes. Unfortunately, if they cannot escape from these compartments, they will be degraded as cellular waste. This limitation directly impacts their therapeutic potential, as only a small fraction of ASOs manage to escape.

Insights from Research

In a collaborative effort outlined in the journal Nature Communications, an international team, including experts from Roche, employed CRISPR/Cas9 technology to investigate factors that affect ASO activity. Their findings provided critical insight into enhancing the efficiency of RNA therapies. The primary goal was to identify genetic factors that could influence the activity of ASOs.

Key Findings

The researchers conducted a genome-wide screen, systematically knocking out thousands of genes to analyze their impact on ASO performance. Among various discoveries, they identified that the gene AP1M1 regulates the transport process from endosomes to lysosomes.

“By selectively switching off this gene, ASOs remain longer in specific endosomes, which increases their chances of escaping and exerting therapeutic effects,” explained Dr. Filip Roudnicky, a senior researcher at Roche.

Prolonged Endosomal Residence Time

The researchers found that the duration ASOs stay in endosomes is a crucial factor for their efficacy. Particularly, they observed that longer residence time enhances the likelihood of escape from endosomes, thus improving their therapeutic actions. This research indicates that transporting behavior within cells can dictate the success of these genetic therapies without necessitating increased dosages.

Implications for Future Therapies

The team's findings present a foundation for enhancing ASO efficiency by providing insight into optimizing drug delivery mechanisms. In a relevant study with cellular and animal models, researchers demonstrated that manipulating endosomal transport notably improved ASO efficacy.

Broader Relevance

The principles derived from this research may extend beyond ASOs to other therapeutic modalities and even apply to combating bacterial and viral infections. As Dr. Anne Spang noted, “Shortening the endosomal residence time of pathogens could potentially reduce their chance of escaping and replicating within the cell, introducing a novel strategy in infection control.”

Summary of Research Findings

Concluding Remarks

The exploration of the intracellular dynamics of ASOs underscores an essential shift in focus from merely developing better drugs to understanding cellular mechanisms that affect drug effectiveness. By strategically altering the transport properties, researchers can significantly enhance the potential of RNA-based therapies to treat a variety of genetic diseases.

Additional Reading

For more in-depth information on this subject, refer to the original study: A CRISPR/Cas9 screen reveals proteins at the endosome-Golgi interface that modulate cellular anti-sense oligonucleotide activity, published in Nature Communications.

References

• Malong, L., et al. (2025). A CRISPR/Cas9 screen reveals proteins at the endosome-Golgi interface that modulate cellular anti-sense oligonucleotide activity. Nature Communications.
• Copyright: Science X (2025). Slowing RNA drug transport inside cells can boost effectiveness for genetic diseases. Retrieved from Science X.